Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CB307 |
| Trade Name | |
| Synonyms | CB-307|CB 307 |
| Drug Descriptions |
CB307 is a bispecific Humabody that acts as an agonist of TNFRSF9 (CD137) and targets prostate-specific membrane antigen (PSMA) and human serum albumin (HSA), potentially inducing T-cell activation against PSMA-expressing tumor cells and inhibiting tumor growth (PMID: 38593226). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C180592 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + CB307 | Atezolizumab CB307 | 0 | 0 |
| CB307 | CB307 | 0 | 1 |
| CB307 + Pembrolizumab | CB307 Pembrolizumab | 0 | 0 |